Scientists probe why malaria drug works differently in people
NCT ID NCT07373743
Summary
This early research study aims to understand how people's genetic differences affect how their bodies process tafenoquine, an FDA-approved drug that prevents malaria. The study will involve 20 healthy adults aged 18-65 who will take a single dose of the drug. Researchers will measure drug levels in blood and urine over two months to see how genetics influence drug metabolism.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHARMACOKINETIC IN NORMAL POPULATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SUNY Upstate Medical University, Upstate Global Health Institute
East Syracuse, New York, 13057, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.